Spironolactone Ceva Uniunea Europeană - croată - EMA (European Medicines Agency)

spironolactone ceva

ceva santé animale - spironolakton - diuretici - psi - za upotrebu u kombinaciji sa standardnom terapijom (uključujući i diuretsku podršku, gdje je to potrebno) za liječenje kongestivnog zatajenja srca uzrokovanog ventilskom regurgitacijom kod pasa.

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Uniunea Europeană - croată - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Olanzapine Cipla (previously Olanzapine Neopharma) Uniunea Europeană - croată - EMA (European Medicines Agency)

olanzapine cipla (previously olanzapine neopharma)

cipla (eu) limited - olanzapin - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine indiciran za liječenje shizofrenije. Оланзапин učinkovit u održavanju kliničkog poboljšanja u roku od nastavka terapije kod pacijenata koji su pokazali odgovor na liječenje . Оланзапин je indiciran za liječenje umjerene do teških maničnih epizoda. kod pacijenata epizoda kojega je manično reagirao na liječenje Оланзапин, Оланзапин je indiciran za prevenciju relapsa kod pacijenata s bipolarnim poremećajem.

RINGEROV LAKTAT Fresenius Kabi otopina za infuziju 6 g/1 L+ 3,17 g/1 L+ 0,4 g/1 L+ 0,27 g/1 L otopina za infuziju Bosnia și Herțegovina - croată - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ringerov laktat fresenius kabi otopina za infuziju 6 g/1 l+ 3,17 g/1 l+ 0,4 g/1 l+ 0,27 g/1 l otopina za infuziju

amicus pharma d.o.o. - kalcijumhlorid, kalijumhlorid, natrijumhlorid, natrijumlaktat - otopina za infuziju - 6 g/1 l+ 3,17 g/1 l+ 0,4 g/1 l+ 0,27 g/1 l - 1000 ml otopine za infuziju sadrži: natrijev hlorid 6.00 g, natrijev laktat, otopina 6.34 g (odgovara 3.17 g natrijevog laktata), kalijev hlorid 0.40 g, kalcijev hlorid dihidrat 0.27 g